The Brigham and Women's Hospital, Inc.

Invictus Oncology Pvt. Ltd.

Hemant Suryavanshi

Shiladitya Sengupta

Monideepa Roy

Ashish Kulkarni

Anubhab Mukherjee

Goutam Biswas

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof. 

Growing community of inventors

Delhi, India

Hemant Suryavanshi